Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3025–3048 of 85,985 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: OMP-54F28, Nab-Paclitaxel and Gemcitabine; Drug
Lead sponsor: OncoMed Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 2 more

Conditions: Breast Cancer
Interventions: Exercise Training, Chemo only; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions: Durvalumab, Tremelimumab; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Critically Ill, Respiratory Failure
Interventions: Thiamine; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anastomotic Stricture, Morbid Obesity
Interventions: Esomeprazole; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Endometrial Cancer
Interventions: Abemaciclib, Letrozole; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 29
States / cities: Mobile, Alabama • Anchorage, Alaska • Greenwich, Connecticut + 24 more

Conditions: Smoldering Plasma Cell Myeloma
Interventions: Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration; Biological · Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 742
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more

Conditions: Opioid Dependence, Buprenorphine Withdrawal Syndrome
Interventions: Lofexidine HCl, Lofexidine-matching sugar pill; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 55
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 32 more

Conditions: Newly Diagnosed High-Grade Gliomas, Diffuse Intrinsic Pontine Glioma
Interventions: Temozolomide, Bevacizumab, Irinotecan; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years to 30 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • Cincinnati, Ohio

Conditions: Colorectal Cancer
Interventions: Capecitabine and Cetuximab; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions: Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Radiation Therapy, Sigmoidoscopy, Total Mesorectal Excision; Procedure · Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 213
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 145 more

Conditions: Diet, Food and Nutrition, Accidental Falls, Cardiovascular Diseases, Diabetes, Debility, Frailty, Functional Disability
Interventions: Meals + RD services, Meals + OT services, Meals + RD + OT services; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 60 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Cigarette Smoking, Computed Tomography, Positron Emission Tomography, Questionnaire Administration; Behavioral · Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cardiovascular Disease
Interventions: Vascular surgery with best medical treatment, Coronary artery bypass grafting (CABG), Percutaneous transluminal coronary angioplasty (PTCA); Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 18
States / cities: Tucson, Arizona • No. Little Rock, Arkansas • San Francisco, California + 15 more

Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Carboplatin, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Relatlimab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 90
States / cities: Dublin, California • Fremont, California • Fresno, California + 69 more

Conditions: Uterine Neoplasms, Endometrial Neoplasms
Interventions: Not listed
Lead sponsor: University of New Mexico; Other
Eligibility: Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1998
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Healthy Adults
Interventions: Dietary; Other
Lead sponsor: United States Department of Agriculture (USDA); Federal
Eligibility: 50 Years to 69 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: Intermittent Claudication
Interventions: Cilostazol; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Mellitus, Hypertension, Hyperlipidemia
Interventions: Monthly Financial Incentive, Final Financial Incentive; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Visual Acuity
Interventions: CONTROL Lens, TEST Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 6
States / cities: San Francisco, California • Jacksonville, Florida • Vestal, New York + 3 more

Conditions: Ulcerative Colitis
Interventions: ALTB-268; Biological
Lead sponsor: AltruBio Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 23
States / cities: San Diego, California • Littleton, Colorado • Miami, Florida + 20 more

Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Primary Peritoneal Cavity Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Primary Peritoneal Cavity Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
Interventions: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, sirolimus, laboratory biomarker analysis, sargramostim; Biological · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Chemotherapy-induced Thrombocytopenia
Interventions: Romiplostim, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Ogden, Utah • Spokane, Washington

Search by objective public record fields.

Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

The Effect of Thiamine vs. Placebo on VO2 in Critical Illness

Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery

Abemaciclib and Letrozole to Treat Endometrial Cancer

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients

A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients

A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas

First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

Occupational Therapy and Registered Dietitian Services to Reduce Fall Risk Among Home Delivered Meal Clients

Free-Base Nicotine or Nicotine Salt e-Liquids in Current E-Cigarette Smokers, PeloPET Study

Does Prophylactic Coronary Artery Revascularization for High Risk Patients Reduce Long-term Risk of Mortality

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Colony-Stimulating Factor-1 (CSF-1) and Other Cytokines in Human Endometrial Carcinogenesis

Pilot Study of a Dietary Intervention Based Upon Advanced Glycation End Products

Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions

Financial Incentives for Medication Adherence

Initial Evaluation of Investigational Lenses Manufactured on a New Production Line

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer